Benefits
Studied alongside prescription metronidazole
Premenopausal women with BV received oral metronidazole plus GR-1 + RC-14 (1x10^9 each) twice daily for 30 days versus placebo. In that trial 88% of the probiotic group were cured versus 40% on placebo (P<0.001), and the placebo group had more residual and intermediate flora. Read it with two limits in mind. Everyone in the trial also took a prescription antibiotic, so the result says nothing about the strains used on their own. And this 2006 finding is the strongest positive result cited on this page: later trials in other populations did not reproduce it. A 2009 trial paired the strains with a single 2 g dose of tinidazole and also reported improved cure rates, again alongside a prescription antibiotic.
Healthy women vaginal flora restoration
In 64 healthy women over 60 days, 37% had restoration to normal lactobacilli flora versus 13% on placebo (P=0.02), with an increase in lactobacilli and reductions in yeast and coliforms. This is the one positive result on this page from the strains taken on their own, without an antibiotic, and it is worth being clear about what it measured: flora composition in women who had no symptoms, not relief of any symptom. Note also that the strains were published here as L. rhamnosus GR-1 plus L. fermentum RC-14.
HIV-women 6-month trial — negative primary outcome
A 6-month trial in HIV-positive women was negative for BV cure rate enhancement, though an intermediate-flora subgroup showed beneficial vaginal pH. Important honest counter-evidence: efficacy may be population-dependent, and HIV-positive vaginal microbiota may not respond like HIV-negative populations.
Chinese cohort BV adjunct — negative
A prospective, parallel-group randomized trial in a Chinese cohort added the strains to metronidazole for 30 days and was negative on its primary outcome. Total cure at 30 days was 57.69% with the probiotic adjunct versus 59.57% with metronidazole alone, and at 90 days 36.54% versus 48.94% (p=0.213), so the adjunct group was numerically worse at 90 days. Differences in baseline vaginal microbiota between populations are one proposed explanation, but the result stands as negative.
Pregnancy trial: null on efficacy, useful safety data
A trial in low-risk pregnant women (66 completed) gave 2.5x10^9 of each strain twice daily for 12 weeks and measured vaginal microbiota, cytokines, and chemokines. It was null on efficacy: the Nugent score returned to normal in 30% of women in both the probiotic and the placebo group at 28 weeks, with no significant difference between them. Its real contribution is safety: no adverse issues were reported from 12 weeks of use in pregnancy.
Uncited: vaginitis 348-women monotherapy (Cheng et al.)
A study in 348 women with vaginitis over a 28-day antibiotic-free course is reported to have found over 90% satisfaction. It is not among the references on this page, so it is uncited and unverified here and should not be relied on. Satisfaction is also a subjective report rather than an efficacy outcome, so it cannot be compared with the cure rates measured in the controlled trials above.
Lactic acid + H₂O₂ + bacteriocin antimicrobial activity
Lactobacilli of this type are described as producing lactic acid (which helps hold vaginal pH at or below 4.5), hydrogen peroxide, and bacteriocins, with antimicrobial activity in laboratory tests against Gardnerella, Mobiluncus, and Prevotella. This card is uncited: none of the human trials referenced on this page measured any of it, so treat it as a proposed explanation rather than evidence of a clinical effect.
Mechanism of action
Lactic acid + low vaginal pH maintenance
Glycogen fermentation produces lactic acid, maintaining vaginal pH ≤4.5 — the foundational protective mechanism that suppresses BV-associated anaerobes.
H₂O₂ antimicrobial production
Hydrogen peroxide production has been described for these lactobacilli, with antimicrobial activity in the laboratory against organisms associated with bacterial vaginosis (Gardnerella vaginalis, Mobiluncus spp., Prevotella spp.). None of the cited human trials measured this.
Bacteriocin secretion
Bacteriocin secretion provides additional targeted antimicrobial activity beyond the acid + H₂O₂ effects — strain-specific molecular antimicrobials.
Oral-vaginal axis (translocation)
Oral capsule administration delivers strains that translocate to the vaginal niche, demonstrated with 37% versus 13% placebo lactobacilli restoration. Distinguishes from intravaginal probiotic delivery.
Lactobacilli niche restoration
Evidence of lactobacilli restoration with concurrent yeast depletion and coliform reduction, restoring the protective Lactobacillus-dominant microbial community rather than just adding the supplemented strains.
Cytokine/chemokine modulation (pregnancy)
The pregnancy trial measured cytokines and chemokines alongside the vaginal microbiota. Immunomodulation remains a proposed mechanism rather than an established one here, since that trial was null on its efficacy outcome.
Clinical trials
Clinical evidence on Lactobacillus rhamnosus GR-1 + L. reuteri RC-14 (Femdophilus / Jarro-Dophilus EPS) for the indications and outcomes described.
Clinical population described in trial publication.
Anukam K et al. 2006. 125 premenopausal BV women received oral metronidazole 500 mg BID days 1-7 plus GR-1 + RC-14 (1×10⁹ each) BID days 1-30 vs placebo. 88% cured (probiotic) vs 40% (placebo) at day 30 (P<0.001). Both arms received the prescription antibiotic, so the trial measures what the strains added to metronidazole, not what they do alone. This is the strongest positive result cited on this page, and the later trials (2010, 2020, 2021) did not reproduce it.
Clinical evidence on Lactobacillus rhamnosus GR-1 + L. reuteri RC-14 (Femdophilus / Jarro-Dophilus EPS) for the indications and outcomes described.
Clinical population described in trial publication.
Reid G et al. 2003. 64 healthy women × 60 days. 37% restoration to normal lactobacilli flora vs 13% placebo (P=0.02). Significant lactobacilli increase, yeast depletion, coliform reduction. Original trial used L. fermentum RC-14 designation, since reclassified to L. reuteri RC-14.
Clinical evidence on Lactobacillus rhamnosus GR-1 + L. reuteri RC-14 (Femdophilus / Jarro-Dophilus EPS) for the indications and outcomes described.
Clinical population described in trial publication.
Hummelen R et al. 2010. 65 HIV-positive women × 6 months. Negative primary BV cure rate enhancement; intermediate-flora subgroup showed beneficial vaginal pH (OR 3.8, P=0.02). Important honest counter-evidence — efficacy may be population-dependent.